AlphAIAlphAI — Financial news for AI agents
seekingalpha.com$ZTS

Zoetis narrows 2026 revenue outlook to $9.22B-$9.32B while raising adjusted EPS to $6.25-$6.35 (NYSE:ZTS)

Zoetis (ZTS) reported Q3 2026 results with revenue and adjusted net income declining as expected. The company narrowed its 2026 revenue outlook to $9.22B-$9.32B and raised adjusted EPS guidance to $6.25-$6.35. CEO Kristin Peck noted challenging dynamics persist.

Original reporting
seekingalpha.com
Published Nov 6, 2026, 10:26 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 10:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ZTS
Bullish
high confidence
Mentioned
$ZTS
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$ZTSBullishHigh
01

Why it matters

The raised EPS and narrowed revenue range suggest better-than-expected performance, likely supporting a price rally.

02

Market read

First report of Zoetis' 2026 guidance; material numbers for investors.

03

What to watch

Potential cost pressures or regulatory risks not addressed in the brief guidance release.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Zoetis, a leading animal health company, released its Q3 2026 earnings call with updated guidance.

Company-level read

Ticker impact

$ZTSBullishHigh confidence
Context

Zoetis narrowed its 2026 revenue outlook to $9.22B‑$9.32B and raised adjusted EPS guidance to $6.25‑$6.35.

Expected impact

upward pressure as investors price in higher earnings outlook

Evidence & confidence

The new guidance is materially above prior expectations and is the first report of these numbers.

Market effects

Sector

Animal health sector may see a lift as Zoetis signals stronger demand.

Regional

U.S. biotech/healthcare indices could gain modestly.

Global

Limited to investors tracking large‑cap pharma and animal health stocks.

Counterpoint

What could challenge this read

If the guidance is already priced in, the stock could face a short‑term pullback.

Key entities

  • Company
    Zoetis Inc.

    Animal health pharmaceutical company.

  • Executive
    Kristin Peck

    CEO & Director of Zoetis.

Read at source← All news

StoryZoetis reports Q3 2026 results, beats EPS and raises full‑year guidance

Also covered by

5 outlets

Related articles

$ZTSMedAI 8/10

Zoetis (ZTS) Q3 2026 Earnings Call Transcript

Zoetis (ZTS) reported Q3 2026 earnings with revenue and adjusted net income declining as expected. The company cited challenges in pet care due to rising costs and changing pet ownership trends, while livestock demand remains strong. Zoetis narrowed its full-year revenue guidance to the high end of its range and highlighted investments in key franchises and innovation.

finance.yahoo.com
$ZTSMedAI 8/10

Zoetis 3Q 2026: Revenue $2.39B, EPS $1.44 — 10-Q Summary

Zoetis reported 3Q 2026 revenue of $2.39B, down 1% YoY, and net income of $1.44B, down 18%. Declines were driven by softer U.S. companion-animal demand, competition, and lower prices, partially offset by livestock growth and favorable exchange rates. Higher restructuring costs also impacted earnings. U.S. companion-animal revenue fell 8%, while U.S. livestock and international revenues rose 5% and 4%, respectively.

tradingview.com
$ZTSHighAI 8/10

Why is Zoetis stock climbing today?

Zoetis (ZTS) stock rose 2.4% premarket after Q3 2026 earnings beat estimates, with adjusted EPS of $1.75 vs. $1.51 and revenue of $2.4B vs. $2.3B. The company raised full-year EPS guidance to $6.25–$6.35. International sales grew 4%, while U.S. companion animal business faced challenges. The stock traded near $91.30 premarket, below its 52-week high of $132.49.

investing.com